老年胃癌患者血清中miR-483-5p表达水平及其临床意义

顾挺; 刘晓庆; 曹凤; 张峰波

doi:10.16766/j.cnki.issn.1674-4152.002263

老年胃癌患者血清中miR-483-5p表达水平及其临床意义

doi: 10.16766/j.cnki.issn.1674-4152.002263

顾挺¹,
刘晓庆²,
曹凤^1, ,,
张峰波¹

1.
新疆医科大学第一附属医院检验科，新疆乌鲁木齐 830054
2.
乌鲁木齐市水磨沟区人民医院检验科，新疆乌鲁木齐 830054

基金项目:

国家自然科学基金项目 81860352

详细信息

通讯作者:
曹凤，E-mail: rhlj1989@163.com

中图分类号: R735.2 R730.43
计量
- 文章访问数: 482
- HTML全文浏览量: 161
- PDF下载量: 60
- 被引次数: 0
出版历程
- 收稿日期: 2021-03-21
- 网络出版日期: 2022-03-03

Serum expression levels and clinical significance of miR-483-5p in elderly patients with gastric cancer

1.
Clinical Test Lab, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830054, China

摘要

摘要: 目的探讨老年胃癌患者血清miR-483-5p相对表达水平及其临床意义。方法纳入2017年1月1日—2019年1月1日于新疆医科大学第一附属医院就诊的65例老年胃癌患者及40例健康者作为研究对象。采用RT-PCR法检测并比较2组血清中miR-483-5p相对表达水平的差异及其与临床特征之间的关系。血清miR-483-5p相对表达水平的影响因素采用logistic回归分析，利用ROC曲线分析血清miR-483-5p相对表达水平在诊断老年胃癌中的临床效能。结果老年胃癌患者血清中miR-483-5p相对表达水平(0.654±0.025)显著高于对照组(0.243±0.023，P < 0.001)。侵犯层次(OR=4.123)、TNM分期(OR=3.548)、淋巴结转移(OR=4.015)均是老年胃癌患者血清miR-483-5p相对表达水平升高的危险因素。血清miR-483-5p相对表达水平诊断老年胃癌的曲线下面积为0.937(95% CI: 0.848~0.966)，当截断值为0.812时，诊断灵敏度和特异度分别为91.2%和95.3%。结论老年胃癌患者血清miR-483-5p相对表达水平显著升高，其表达水平与胃癌的临床特征密切相关，可作为筛查胃癌的一项生物学标志物。
- MiR-483-5p /
- 胃癌 /
- ROC曲线 /
- 临床特征 /
- 血清学指标
Abstract: Objective To investigate the relative expression levels of serum miR-483-5p and its clinical significance in elderly patients with gastric cancer. Methods A total of 65 elderly patients with gastric cancer and 40 healthy individuals were enrolled in the First Affiliated Hospital of Xinjiang Medical University between January 1, 2017, and January 1, 2019. The difference in the relative expression levels of serum miR-483-5p amongst the subjects was detected and compared by RT-PCR. The relationship between the relative expression levels of serum miR-483-5p and clinical characteristics of elderly patients with gastric cancer was also analysed. The influencing factors affecting the relative expression levels of serum miR-483-5p were analysed by Logistic regression analysis. The clinical efficacy of miR-483-5p in the diagnosis of gastric cancer was analysed by the receiver operating characteristic (ROC) curve. Results Compared with the control group, the relative expression levels of serum miR-483-5p in elderly patients with gastric cancer were significantly higher (P < 0.001). The invasion levels (OR=4.123), TNM stage (OR=3.548) and lymph node metastasis (OR=4.015) were considered as the risk factors for the increased serum relative expression levels of miR-483-5p in elderly patients with gastric cancer. The ROC curve showed that the relative expression levels of serum miR-483-5p had a high clinical efficacy in the diagnosis of gastric cancer. Therefore, at a cutoff value of 0.812, the sensitivity and specificity were 91.2% and 95.3%, respectively. Conclusion The serum relative expression levels of miR-483-5p in elderly patients with gastric cancer are significantly high and related to the clinical characteristics. Therefore, miR-483-5p may be considered as a potential biomarker for gastric cancer screening.
- MiR-483-5p /
- Gastric cancer /
- ROC curve /
- Clinical characteristics /
- Serological indicators

HTML全文

图 1 2组研究对象血清miR-483-5p相对表达水平比较

下载: 全尺寸图片幻灯片

图 2 血清miR-483-5p相对表达水平诊断胃癌的临床效能

下载: 全尺寸图片幻灯片

表 1 65例老年胃癌患者血清miR-483-5p相对表达水平与临床特征的关系

项目	例数	miR-483-5p 相对表达水平	统计量	P值
年龄(岁)			1.399^a	0.167
≥60	37	0.652±0.009
< 60	28	0.656±0.014
性别			0.948^a	0.347
男性	40	0.653±0.007
女性	25	0.655±0.010
肿瘤灶直径(cm)			55.069^a	< 0.001
< 5	47	0.546±0.008
≥5	18	0.682±0.011
肿瘤分级			34.458^b	< 0.001
低分化	26	0.698(0.543，0.712)
高分化	39	0.504(0.203，0.686)
侵犯层次			59.508^a	< 0.001
T1/T2	24	0.506±0.014
T3/T4	41	0.668±0.008
TNM分期			43.481^a	< 0.001
Ⅰ/Ⅱ期	25	0.449±0.021
Ⅲ/Ⅳ期	40	0.675±0.020
淋巴结转移			20.186^b	< 0.001
有	32	0.683(0.486，0.765)
无	33	0.518(0.348，0.732)
注：^a为t值，^b为Z值。

下载: 导出CSV

表 2 变量赋值方式

变量	赋值方式
性别	男性=0;女性=1
年龄	< 60岁=0;≥60岁=1
肿瘤灶直径	< 5 cm=0；≥5 cm=1
肿瘤分级	高分化=0；低分化=1
侵犯层次	T1/T2=0；T3/T4=1
TNM分期	Ⅰ/Ⅱ期=0；Ⅲ/Ⅳ期=1
淋巴结转移	无=0；有=1

下载: 导出CSV

表 3 老年胃癌患者血清miR-483-5p相对表达水平的影响因素

项目	B	SE	Wald χ²	P值	OR(95% CI)
侵犯层次	1.417	3.658	0.150	< 0.001	4.123(1.148~5.974)
TNM分期	1.266	4.112	0.094	< 0.001	3.548(2.276~6.087)
淋巴结转移	1.390	5.115	0.073	< 0.001	4.015(2.615~9.844)

下载: 导出CSV

参考文献(20)

[1]	左婷婷, 郑荣寿, 曾红梅, 等. 中国胃癌流行病学现状[J]. 中国肿瘤临床, 2017, 44(1): 52-58. doi: 10.3969/j.issn.1000-8179.2017.01.881
[2]	ROCKEN C. Molecular classification of gastric cancer[J]. Expert Rev Mol Diagn, 2017, 17(3): 293-301. doi: 10.1080/14737159.2017.1286985
[3]	LU T X, ROTHENBERG M E. MicroRNA[J]. J Allergy Clin Immunol, 2018, 141(4): 1202-1207. doi: 10.1016/j.jaci.2017.08.034
[4]	田衍, 舒若, 曾玉剑, 等. miRNA-329和Tiam1在胃癌中的表达及其临床意义[J]. 重庆医学, 2019, 48(12): 2006-2008, 2013. doi: 10.3969/j.issn.1671-8348.2019.12.006
[5]	姜晓娟, 江啸, 王芙蓉, 等. 微小RNA-218表达在胃癌中的作用机制研究进展[J]. 中华实验外科杂志, 2019, 36(6): 1154-1157. doi: 10.3760/cma.j.issn.1001-9030.2019.06.057
[6]	CORMEDI M C V, KATAYAMA M L H, GUINDALINI R S C, et al. Survival and prognosis of young adults with gastric cancer[J]. Clinics, 2018, 73(suppl 1): e651s. http://www.scielo.br/pdf/clin/v73s1/1807-5932-clin-73-e651s.pdf
[7]	吴永伟, 赵刚. CEA、CA724、CA199与PGI、PGⅡ、PGR联合检测在胃癌早期诊断中的价值分析[J]. 川北医学院学报, 2018, 33(6): 836-839. doi: 10.3969/j.issn.1005-3697.2018.06.008
[8]	张美华, 薛静, 辛勇, 等. 胰腺癌患者化疗前后血红蛋白、癌胚抗原、糖类抗原19-9和糖类抗原125、糖类抗原50水平变化与价值研究[J]. 实验与检验医学, 2019, 37(3): 505-507. doi: 10.3969/j.issn.1674-1129.2019.03.051
[9]	迪米拉·阿里根, 帕尔哈提·阿布都热衣木, 张丽博. 双歧杆菌三联活菌辅助XELOX方案对结直肠癌术后抗肿瘤免疫应答和肿瘤标志物的影响[J]. 中国临床研究, 2019, 32(4): 516-519. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGCK201904021.htm
[10]	SALIMINEJAD K, KHORRAM KHORSHID H R, SOLEYMANI FARD S, et al. An overview of microRNAs: Biology, functions, therapeutics, and analysis methods[J]. J Cell Physiol, 2018, 234(5): 5451-5465. http://www.ncbi.nlm.nih.gov/pubmed/30471116
[11]	MAO Y, LIU R, ZHOU H, et al. Transcriptome analysis of miRNA-lncRNA-mRNA interactions in the malignant transformation process of gastric cancer initiation[J]. Cancer Gene Ther, 2017, 24(6): 267-275. doi: 10.1038/cgt.2017.14
[12]	HAO N B, HE Y F, LI X Q, et al. The role of miRNA and lncRNA in gastric cancer[J]. Oncotarget, 2017, 8(46): 81572-81582. doi: 10.18632/oncotarget.19197
[13]	顾玮, 胡梅洁, 孙颖, 等. 胃癌外周血微小核糖核酸表达谱的初步分析[J]. 中华消化杂志, 2012, 32(4): 222-225. doi: 10.3760/cma.j.issn.0254-1432.2012.04.002
[14]	李茶香, 罗云春, 胡汉卿. 微小RNA-483-5p在肝癌组织的表达及其临床意义[J]. 中华实验外科杂志, 2018, 35(6): 1137-1139. doi: 10.3760/cma.j.issn.1001-9030.2018.06.041
[15]	XUE L, NAN J, DONG L, et al. Upregulated miR-483-5p expression as a prognostic biomarker for esophageal squamous cell carcinoma[J]. Cancer Biomark, 2017, 19(2): 193-197. doi: 10.3233/CBM-160506
[16]	韩涛, 刘星, 张双鹤, 等. 胃癌细胞株MKN-45肿瘤干细胞中microRNA差异表达研究[J]. 临床军医杂志, 2017, 45(1): 5-8. https://www.cnki.com.cn/Article/CJFDTOTAL-JYGZ201701002.htm
[17]	WU K, MA L A, ZHU J X. MiR-483-5p promotes growth, invasion and self-renewal of gastric cancer stem cells by Wnt/b-catenin signaling[J]. Mol Med Rep, 2016, 14(4): 3421-3428. doi: 10.3892/mmr.2016.5603
[18]	秦文, 赵楠楠, 韩永焕, 等. ZNF436在胃癌中的表达及调控WNT/β-catenin对胃癌细胞迁移及侵袭的影响[J]. 实用肿瘤学杂志, 2019, 33(3): 222-227. https://www.cnki.com.cn/Article/CJFDTOTAL-SYZL201903007.htm
[19]	AGOSTA C, LAUGIER J, GUYON L, et al. MiR-483-5p and miR-139-5p promote aggressiveness by targeting N-Myc Downstream-Regulated Gene family members in adrenocortical cancer[J]. Int J Cancer, 2018, 143(4): 994-957. http://smartsearch.nstl.gov.cn/paper_detail.html?id=22130c0f04ef9bad46fe4e051b9944fd
[20]	洪莲莲, 吴盈利, 陈香浏, 等. 氧胁迫条件下胃癌细胞中N-myc下游调节基因4的功能变化[J]. 中华实验外科杂志, 2018, 35(4): 606-609. doi: 10.3760/cma.j.issn.1001-9030.2018.04.002